Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
EDAP TMS S.A. EDAP
$11.15
+$0.04 (0.36%)
На 18:01, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
415063976.00000000
-
week52high
12.65
-
week52low
6.02
-
Revenue
55109000
-
P/E TTM
-62
-
Beta
1.24429000
-
EPS
-0.10000000
-
Last Dividend
0.00000000
-
Next Earnings Date
17 мая 2023 г. в 12:30
Описание компании
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 19 ноя 2021 г. |
| Piper Sandler | Overweight | 28 апр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 01 апр 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 21 янв 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 20 ноя 2020 г. |
| Jefferies | Buy | 01 ноя 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 18 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023
GlobeNewsWire
03 мая 2023 г. в 08:00
- Company to host conference call and webcast on Wednesday, May 1 7 th at 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2023 before the markets open on Wednesday, May 17th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer, and Ken Mobeck, Chief Financial Officer of the U.S. Subsidiary.
EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th
GlobeNewsWire
09 мар 2023 г. в 08:00
LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023.
EDAP: Potential Crossover Of HIFU To Endometriosis Additional Inflection Points
Seeking Alpha
03 февр 2023 г. в 18:54
EDAP continues to rate higher in 2023. Positive phase 2 data investigating HIFU in rectal endometriosis adds another inflection point for investors to work by.
EDAP TMS S.A. (EDAP) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks Investment Research
30 ноя 2022 г. в 10:32
EDAP TMS S.A. (EDAP) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
New Strong Buy Stocks for November 21st
Zacks Investment Research
21 ноя 2022 г. в 09:47
AMRK, ACR, EDAP, H and ENTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2022.